Integrative Computational and Experimental Approaches to Establish a Post-Myocardial Infarction Knowledge Map

PLoS Computational Biology

Volumn 10, Issue 3, 2014, Pages

  Nguyen, Nguyen T ^a,b   Zhang, Xiaolin ^a   Wu, Cathy ^c   Lange, Richard A ^b   Chilton, Robert J ^b   Lindsey, Merry L ^b,d,e   Jin, Yu Fang ^a,b  

^a The University of Texas at San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF DELAWARE   (United States)

^d UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^e G V SONNY MONTGOMERY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLOGY; CLINICAL RESEARCH; DATA MINING; DIAGNOSIS; MOLECULAR BIOLOGY; MOLECULAR INTERACTIONS;

CARDIOVASCULAR DISEASE; CLINICAL DIAGNOSTICS; COMPUTATIONAL APPROACH; DIAGNOSTIC MARKERS; EXPERIMENTAL APPROACHES; KNOWLEDGE MAP; LEFT VENTRICLES; MYOCARDIAL INFARCTION; PROTEIN-PROTEIN INTERACTION NETWORKS; RESEARCH EFFORTS;

PROTEINS;

ARTICLE; CELL MEMBRANE; DATA MINING; EXTRACELLULAR MATRIX; GENETIC TRANSCRIPTION; HEART INFARCTION; HEART VENTRICLE REMODELING; HUMAN; INFLAMMATION; KNOWLEDGE BASE; MEDLINE; MOLECULAR INTERACTION; PREDICTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE;

ALGORITHMS; BIOLOGICAL MARKERS; CLUSTER ANALYSIS; COMPUTER SIMULATION; DATA MINING; DATABASES, PROTEIN; EXTRACELLULAR MATRIX; HEART VENTRICLES; HUMANS; MEDICAL INFORMATICS; MODELS, BIOLOGICAL; MYOCARDIAL INFARCTION; PROTEIN INTERACTION MAPPING; VENTRICULAR REMODELING;

EID: 84897392079     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1003472     Document Type: Article

References (164)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, et al. (2013) Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 127: e6-e245.
2. Alpert JS, Thygesen K, Antman E, Bassand JP, (2000) Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36: 959-969.
3. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, et al. (2006) Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 113: 2089-2096.
4. Booz GW, Baker KM, (1995) Molecular signalling mechanisms controlling growth and function of cardiac fibroblasts. Cardiovasc Res 30: 537-543.
5. Broverman RL, Nguyen KH, da Silveira A, Brinkley LL, Macauley SP, et al. (1998) Changes in the expression of extracellular matrix (ECM) and matrix metalloproteinases (MMP) of proliferating rat parotid acinar cells. J Dent Res 77: 1504-1514.
6. Galvez BG, Matias-Roman S, Yanez-Mo M, Sanchez-Madrid F, Arroyo AG, (2002) ECM regulates MT1-MMP localization with beta1 or alphavbeta3 integrins at distinct cell compartments modulating its internalization and activity on human endothelial cells. J Cell Biol 159: 509-521.
7. Ma Y, Chiao YA, Zhang J, Manicone AM, Jin YF, et al. (2012) Matrix metalloproteinase-28 deletion amplifies inflammatory and extracellular matrix responses to cardiac aging. Microsc Microanal 18: 81-90.
8. Zamilpa R, Ibarra J, de Castro Bras LE, Ramirez TA, Nguyen N, et al. (2012) Transgenic overexpression of matrix metalloproteinase-9 in macrophages attenuates the inflammatory response and improves left ventricular function post-myocardial infarction. J Mol Cell Cardiol 53: 599-608.
9. Oxenham H, Sharpe N, (2000) Angiotensin-converting enzyme inhibitor treatment after myocardial infarction. A selective approach for maximum benefit. J Am Coll Cardiol 36: 2054-2055.
10. Ribichini F, Wijns W, (2002) Acute myocardial infarction: reperfusion treatment. Heart 88: 298-305.
11. Shiffman D, Kane JP, Louie JZ, Arellano AR, Ross DA, et al. (2008) Analysis of 17,576 potentially functional SNPs in three case-control studies of myocardial infarction. PLoS One 3: e2895.
12. Kathiresan S, Voight BF, Purcell S, Musunuru K, Ardissino D, et al. (2009) Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 41: 334-341.
13. http://www.nhlbi.nih.gov/resources/pga/ Genomics of Cardiovascular Development, Adaptation, and Remodeling. NHLBI Program for Genomic Applications, Harvard Medical School.
14. Brun C, Chevenet F, Martin D, Wojcik J, Guenoche A, et al. (2004) Functional classification of proteins for the prediction of cellular function from a protein-protein interaction network. Genome Biology 5: R6.
15. Kritikos GD, Moschopoulos C, Vazirgiannis M, Kossida S, (2011) Noise reduction in protein-protein interaction graphs by the implementation of a novel weighting scheme. BMC Bioinformatics 12: 239.
16. Nabieva E, Jim K, Agarwal A, Chazelle B, Singh M, (2005) Whole-proteome prediction of protein function via graph-theoretic analysis of interaction maps. Bioinformatics 21 Suppl 1: i302-310.
17. Levy ED, Pereira-Leal JB, (2008) Evolution and dynamics of protein interactions and networks. Curr Opin Struct Biol 18: 349-357.
18. Wachi S, Yoneda K, Wu R, (2005) Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues. Bioinformatics 21: 4205-4208.
19. Pujana MA, Han JD, Starita LM, Stevens KN, Tewari M, et al. (2007) Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet 39: 1338-1349.
20. Nguyen N, Xiaolin Z, Yunji W, Hai-Chao H, Yufang J, et al. Targeting myocardial infarction-specific protein interaction network using computational analyses; 2011 4-6 Dec. 2011. pp. 198-201.
21. UniProt-Consortium (2012) Reorganizing the protein space at the Universal Protein Resource (UniProt). Nucleic Acids Research 40: D71-D75.
22. Kamburov A, Stelzl U, Lehrach H, Herwig R, (2013) The ConsensusPathDB interaction database: 2013 update. Nucleic Acids Research 41: D793-800.
23. McKusick VA, (2007) Mendelian Inheritance in Man and its online version, OMIM. Am J Hum Genet 80: 588-604.
24. Barabasi AL, (2009) Scale-free networks: a decade and beyond. Science 325: 412-413.
25. Erdos P, Renyi A, (1960) On the Evolution of Random Graphs. Bulletin of the International Statistical Institute 38: 343-347.
26. Petrovic D, Verhovec R, Globocnik Petrovic M, Osredkar J, Peterlin B, (2007) Association of vascular endothelial growth factor gene polymorphism with myocardial infarction in patients with type 2 diabetes. Cardiology 107: 291-295.
27. Huang dW, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
28. Huang dW, Sherman BT, Lempicki RA, (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Research 37: 1-13.
29. Blair P, Flaumenhaft R, (2009) Platelet alpha-granules: basic biology and clinical correlates. Blood Rev 23: 177-189.
30. Fujihara M, Muroi M, Tanamoto K, Suzuki T, Azuma H, et al. (2003) Molecular mechanisms of macrophage activation and deactivation by lipopolysaccharide: roles of the receptor complex. Pharmacol Ther 100: 171-194.
31. Bujak M, Frangogiannis NG, (2007) The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res 74: 184-195.
32. Dinarello CA, (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117: 3720-3732.
33. Louie B, Bergen S, Higdon R, Kolker E, (2010) Quantifying protein function specificity in the gene ontology. Stand Genomic Sci 2: 238-244.
34. Lofgren B, Povlsen JA, Rasmussen LE, Stottrup NB, Solskov L, et al. (2010) Amino acid transamination is crucial for ischaemic cardioprotection in normal and preconditioned isolated rat hearts- focus on l-glutamate. Experimental Physiology 95: 140-152.
35. Jacobs M, Staufenberger S, Gergs U, Meuter K, Brandstatter K, et al. (1999) Tumor necrosis factor-alpha at acute myocardial infarction in rats and effects on cardiac fibroblasts. J Mol Cell Cardiol 31: 1949-1959.
36. Liu F, Lu GY, Dong NZ, Bai X, Su J, et al. (2005) [A study on the significance of plasma thrombospondin1 in thrombotic thrombocytopenic purpura and the relationship between thrombospondin1 and von Willebrand factor cleaving protease (ADAMTS13)]. Zhonghua Yi Xue Za Zhi 85: 3190-3193.
37. Bell D, Jackson M, Nicoll JJ, Millar A, Dawes J, et al. (1990) Inflammatory response, neutrophil activation, and free radical production after acute myocardial infarction: effect of thrombolytic treatment. Br Heart J 63: 82-87.
38. Dinerman JL, Mehta JL, Saldeen TG, Emerson S, Wallin R, et al. (1990) Increased neutrophil elastase release in unstable angina pectoris and acute myocardial infarction. J Am Coll Cardiol 15: 1559-1563.
39. Kelly D, Khan S, Cockerill G, Ng LL, Thompson M, et al. (2008) Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction. Eur J Heart Fail 10: 133-139.
40. van Dijk A, Niessen HW, Ursem W, Twisk JW, Visser FC, et al. (2008) Accumulation of fibronectin in the heart after myocardial infarction: a putative stimulator of adhesion and proliferation of adipose-derived stem cells. Cell Tissue Res 332: 289-298.
41. Kiec-Wilk B, Surdacki A, Dembinska-Kiec A, Michalowska J, Stachura-Deren M, et al. (2007) Acute myocardial infarction and a new ABCC6 mutation in a 16-year-old boy with pseudoxanthoma elasticum. Int J Cardiol 116: 261-262.
42. Huebener P, Abou-Khamis T, Zymek P, Bujak M, Ying X, et al. (2008) CD44 is critically involved in infarct healing by regulating the inflammatory and fibrotic response. J Immunol 180: 2625-2633.
43. Ip JE, Wu Y, Huang J, Zhang L, Pratt RE, et al. (2007) Mesenchymal stem cells use integrin beta1 not CXC chemokine receptor 4 for myocardial migration and engraftment. Mol Biol Cell 18: 2873-2882.
44. Krishnamurthy P, Lambers E, Verma S, Thorne T, Qin G, et al. (2010) Myocardial knockdown of mRNA-stabilizing protein HuR attenuates post-MI inflammatory response and left ventricular dysfunction in IL-10-null mice. FASEB J 24: 2484-2494.
45. Lindsey ML, Escobar GP, Mukherjee R, Goshorn DK, Sheats NJ, et al. (2006) Matrix metalloproteinase-7 affects connexin-43 levels, electrical conduction, and survival after myocardial infarction. Circulation 113: 2919-2928.
46. Isobe K, Kuba K, Maejima Y, Suzuki J, Kubota S, et al. (2010) Inhibition of endostatin/collagen XVIII deteriorates left ventricular remodeling and heart failure in rat myocardial infarction model. Circ J 74: 109-119.
47. Carrell TW, Burnand KG, Wells GM, Clements JM, Smith A, (2002) Stromelysin-1 (matrix metalloproteinase-3) and tissue inhibitor of metalloproteinase-3 are overexpressed in the wall of abdominal aortic aneurysms. Circulation 105: 477-482.
48. Pai JK, Manson JE, Rexrode KM, Albert CM, Hunter DJ, et al. (2007) Complement factor H (Y402H) polymorphism and risk of coronary heart disease in US men and women. Eur Heart J 28: 1297-1303.
49. Li YY, Feldman AM, Sun Y, McTiernan CF, (1998) Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 98: 1728-1734.
50. Mahajan VS, Jarolim P, (2011) How to interpret elevated cardiac troponin levels. Circulation 124: 2350-2354.
51. Lindsey ML, Escobar GP, Dobrucki LW, Goshorn DK, Bouges S, et al. (2006) Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am J Physiol Heart Circ Physiol 290: H232-239.
52. Lindsey ML, Goshorn DK, Squires CE, Escobar GP, Hendrick JW, et al. (2005) Age-dependent changes in myocardial matrix metalloproteinase/tissue inhibitor of metalloproteinase profiles and fibroblast function. Cardiovasc Res 66: 410-419.
53. Csardi G NT, (2006) The igraph software package for complex network research. InterJournal, Complex Systems.
54. Clauset A, Shalizi CR, Newman MEJ, (2009) Power-Law Distributions in Empirical Data. Siam Review 51: 661-703.
55. Freeman LC, (1979) Centrality in Social Networks Conceptual Clarification. Social Networks 1: 215-239.
56. Wasserman S, Faust K (1994) Social network analysis: methods and applications. Cambridge; New York: Cambridge University Press. xxxi, 825 p. p.
57. Harary F (1969) Graph theory. Reading, Mass.,: Addison-Wesley Pub. Co. ix, 274 p. p.
58. Winter D (2012) rentrez: Entrez in R.
59. Feinerer I, Hornik K (2010) openNLP: openNLP Interface.
60. Wang JZ, Du Z, Payattakool R, Yu PS, Chen CF, (2007) A new method to measure the semantic similarity of GO terms. Bioinformatics 23: 1274-1281.
61. Adamic LA, Adar E, (2003) Friends and neighbors on the Web. Social Networks 25: 210-230.
62. Culp M, (2011) spa: Semi-Supervised Semi-Parametric Graph-Based Estimation in R. Journal of Statistical Software 40: 1-29.
63. Cohen J, (1960) A Coefficient of Agreement for Nominal Scales. Educational and Psychological Measurement 20: 37-46.
64. Parenica J, Goldbergova MP, Kala P, Jarkovsky J, Poloczek M, et al. (2010) ACE gene insertion/deletion polymorphism has a mild influence on the acute development of left ventricular dysfunction in patients with ST elevation myocardial infarction treated with primary PCI. BMC Cardiovasc Disord 10: 60.
65. Messadi E, Vincent MP, Griol-Charhbili V, Mandet C, Colucci J, et al. (2010) Genetically determined angiotensin converting enzyme level and myocardial tolerance to ischemia. FASEB J 24: 4691-4700.
66. Palmer BR, Pilbrow AP, Yandle TG, Frampton CM, Richards AM, et al. (2003) Angiotensin-converting enzyme gene polymorphism interacts with left ventricular ejection fraction and brain natriuretic peptide levels to predict mortality after myocardial infarction. J Am Coll Cardiol 41: 729-736.
67. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, et al. (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291: 1730-1737.
68. Zhang S, He B, Goldstein S, Ge J, Wang Z, et al. (2011) Changes in adiponectin expression in acute myocardial infarction rats and the significance of bisoprolol intervention. Can J Physiol Pharmacol 89: 109-115.
69. Tao L, Gao E, Jiao X, Yuan Y, Li S, et al. (2007) Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 115: 1408-1416.
70. Gunes Y, Okcun B, Kavlak E, Erbas C, Karcier S, (2008) Value of brain natriuretic peptide after acute myocardial infarction. Anadolu Kardiyol Derg 8: 182-187.
71. Xiaozhou H, Jie Z, Li Z, Liyan C, (2006) Predictive value of the serum level of N-terminal pro-brain natriuretic peptide and high-sensitivity C-reactive protein in left ventricular remodeling after acute myocardial infarction. J Clin Lab Anal 20: 19-22.
72. Mayr A, Mair J, Schocke M, Klug G, Pedarnig K, et al. (2011) Predictive value of NT-pro BNP after acute myocardial infarction: relation with acute and chronic infarct size and myocardial function. Int J Cardiol 147: 118-123.
73. Zha Y, Chen Y, Xu F, Li T, Zhao C, et al. (2010) ADAMTS4 level in patients with stable coronary artery disease and acute coronary syndromes. Biomed Pharmacother 64: 160-164.
74. Zhao C, Zha Y, Wu X, Chen L, Shi J, et al. (2011) The quantification of ADAMTS4 and 8 expression and selection of reference genes for quantitative real-time PCR analysis in myocardial infarction. Biomed Pharmacother 65: 555-559.
75. Zha Y, Chen Y, Xu F, Zhang J, Li T, et al. (2010) Elevated level of ADAMTS4 in plasma and peripheral monocytes from patients with acute coronary syndrome. Clin Res Cardiol 99: 781-786.
76. Wagsater D, Bjork H, Zhu C, Bjorkegren J, Valen G, et al. (2008) ADAMTS-4 and-8 are inflammatory regulated enzymes expressed in macrophage-rich areas of human atherosclerotic plaques. Atherosclerosis 196: 514-522.
77. Dewald O, Zymek P, Winkelmann K, Koerting A, Ren G, et al. (2005) CCL2/Monocyte Chemoattractant Protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res 96: 881-889.
78. Xia Y, Frangogiannis NG, (2007) MCP-1/CCL2 as a therapeutic target in myocardial infarction and ischemic cardiomyopathy. Inflamm Allergy Drug Targets 6: 101-107.
79. Morimoto H, Takahashi M, Izawa A, Ise H, Hongo M, et al. (2006) Cardiac overexpression of monocyte chemoattractant protein-1 in transgenic mice prevents cardiac dysfunction and remodeling after myocardial infarction. Circ Res 99: 891-899.
80. Qi L, Ma J, Qi Q, Hartiala J, Allayee H, et al. (2011) Genetic risk score and risk of myocardial infarction in Hispanics. Circulation 123: 374-380.
81. Saade S, Cazier JB, Ghassibe-Sabbagh M, Youhanna S, Badro DA, et al. (2011) Large scale association analysis identifies three susceptibility loci for coronary artery disease. PLoS One 6: e29427.
82. Samani NJ, Braund PS, Erdmann J, Gotz A, Tomaszewski M, et al. (2008) The novel genetic variant predisposing to coronary artery disease in the region of the PSRC1 and CELSR2 genes on chromosome 1 associates with serum cholesterol. J Mol Med (Berl) 86: 1233-1241.
83. Nishiyama Y, Nejima J, Watanabe A, Kotani E, Sakai N, et al. (2001) Ehlers-Danlos syndrome type IV with a unique point mutation in COL3A1 and familial phenotype of myocardial infarction without organic coronary stenosis. J Intern Med 249: 103-108.
84. Muckian C, Fitzgerald A, O'Neill A, O'Byrne A, Fitzgerald DJ, et al. (2002) Genetic variability in the extracellular matrix as a determinant of cardiovascular risk: association of type III collagen COL3A1 polymorphisms with coronary artery disease. Blood 100: 1220-1223.
85. Zaidi SH, Huang Q, Momen A, Riazi A, Husain M, (2010) Growth differentiation factor 5 regulates cardiac repair after myocardial infarction. J Am Coll Cardiol 55: 135-143.
86. Wilson AM, Ryan MC, Boyle AJ, (2006) The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen. Int J Cardiol 106: 291-297.
87. Sakkinen P, Abbott RD, Curb JD, Rodriguez BL, Yano K, et al. (2002) C-reactive protein and myocardial infarction. J Clin Epidemiol 55: 445-451.
88. Lanfear DE, Jones PG, Marsh S, Cresci S, Spertus JA, et al. (2007) Connexin37 (GJA4) genotype predicts survival after an acute coronary syndrome. Am Heart J 154: 561-566.
89. Wong CW, Christen T, Pfenniger A, James RW, Kwak BR, (2007) Do allelic variants of the connexin37 1019 gene polymorphism differentially predict for coronary artery disease and myocardial infarction? Atherosclerosis 191: 355-361.
90. Listi F, Candore G, Lio D, Russo M, Colonna-Romano G, et al. (2005) Association between C1019T polymorphism of connexin37 and acute myocardial infarction: a study in patients from Sicily. Int J Cardiol 102: 269-271.
91. Noto D, Cefalu AB, Barbagallo CM, Pace A, Rizzo M, et al. (2005) Cystatin C levels are decreased in acute myocardial infarction: effect of cystatin C G73A gene polymorphism on plasma levels. Int J Cardiol 101: 213-217.
92. Silva D, Cortez-Dias N, Jorge C, Marques JS, Carrilho-Ferreira P, et al. (2012) Cystatin C as prognostic biomarker in ST-segment elevation acute myocardial infarction. Am J Cardiol 109: 1431-1438.
93. Ichimoto E, Jo K, Kobayashi Y, Inoue T, Nakamura Y, et al. (2009) Prognostic significance of cystatin C in patients with ST-elevation myocardial infarction. Circ J 73: 1669-1673.
94. Medina P, Navarro S, Corral J, Zorio E, Roldan V, et al. (2008) Endothelial protein C receptor polymorphisms and risk of myocardial infarction. Haematologica 93: 1358-1363.
95. Guella I, Duga S, Ardissino D, Merlini PA, Peyvandi F, et al. (2011) Common variants in the haemostatic gene pathway contribute to risk of early-onset myocardial infarction in the Italian population. Thromb Haemost 106: 655-664.
96. Wang J, Yang L, Rezaie AR, Li J, (2011) Activated protein C protects against myocardial ischemic/reperfusion injury through AMP-activated protein kinase signaling. J Thromb Haemost 9: 1308-1317.
97. Sampaio MF, Hirata MH, Hirata RD, Santos FC, Picciotti R, et al. (2007) AMI is associated with polymorphisms in the NOS3 and FGB but not in PAI-1 genes in young adults. Clin Chim Acta 377: 154-162.
98. Mannila MN, Eriksson P, Ericsson CG, Hamsten A, Silveira A, (2006) Epistatic and pleiotropic effects of polymorphisms in the fibrinogen and coagulation factor XIII genes on plasma fibrinogen concentration, fibrin gel structure and risk of myocardial infarction. Thromb Haemost 95: 420-427.
99. Siegerink B, Rosendaal FR, Algra A, (2009) Genetic variation in fibrinogen; its relationship to fibrinogen levels and the risk of myocardial infarction and ischemic stroke. J Thromb Haemost 7: 385-390.
100. Bigalke B, Haap M, Stellos K, Geisler T, Seizer P, et al. (2010) Platelet glycoprotein VI (GPVI) for early identification of acute coronary syndrome in patients with chest pain. Thromb Res 125: e184-189.
101. Bigalke B, Stellos K, Stakos D, Joos T, Potz O, et al. (2009) Influence of platelet count on the expression of platelet collagen receptor glycoprotein VI (GPVI) in patients with acute coronary syndrome. Thromb Haemost 101: 911-915.
102. Croft SA, Samani NJ, Teare MD, Hampton KK, Steeds RP, et al. (2001) Novel platelet membrane glycoprotein VI dimorphism is a risk factor for myocardial infarction. Circulation 104: 1459-1463.
103. Dhillon OS, Narayan HK, Quinn PA, Squire IB, Davies JE, et al. (2011) Interleukin 33 and ST2 in non-ST-elevation myocardial infarction: comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNP. Am Heart J 161: 1163-1170.
104. Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, et al. (2010) Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol 55: 243-250.
105. Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, et al. (2002) Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 106: 2961-2966.
106. Sopel M, Ma I, Gelinas L, Oxner A, Myers T, et al. (2010) Integrins and monocyte migration to the ischemic myocardium. J Invest Surg 23: 79-86.
107. Arslan F, Smeets MB, Riem Vis PW, Karper JC, Quax PH, et al. (2011) Lack of fibronectin-EDA promotes survival and prevents adverse remodeling and heart function deterioration after myocardial infarction. Circ Res 108: 582-592.
108. Legare JF, Oxner A, Heimrath O, Issekutz T, (2007) Infiltration of polymorphonuclear cells into the post-ischaemic myocardium is dependent on beta2 and alpha4 integrins. Int J Exp Pathol 88: 291-300.
109. Martinez-Quintana E, Chirino R, Nieto-Lago V, Perez-Jimenez P, Lopez-Rios L, et al. (2013) Prognostic value of ACE I/D, AT1R A1166C, PAI-I 4G/5G and GPIIIa a1/a2 polymorphisms in myocardial infarction. Cardiol J [epub ahead of print].
110. Sun M, Opavsky MA, Stewart DJ, Rabinovitch M, Dawood F, et al. (2003) Temporal response and localization of integrins beta1 and beta3 in the heart after myocardial infarction: regulation by cytokines. Circulation 107: 1046-1052.
111. Pchelina SN, Sirotkina OV, Sheidina AM, Taraskina AE, Rodygina TI, et al. (2007) [Genetic risk factors for development of myocardial infarction in young men living in North-West region of Russia]. Kardiologiia 47: 29-34.
112. Fujimaki T, Kato K, Yokoi K, Oguri M, Yoshida T, et al. (2010) Association of genetic variants in SEMA3F, CLEC16A, LAMA3, and PCSK2 with myocardial infarction in Japanese individuals. Atherosclerosis 210: 468-473.
113. Kawamiya T, Kato K, Horibe H, Yokoi K, Oguri M, et al. (2010) Association of genetic variants with myocardial infarction in Japanese individuals with or without metabolic syndrome. Exp Ther Med 1: 969-975.
114. Fujimaki T, Kato K, Yoshida T, Oguri M, Watanabe S, et al. (2009) Association of genetic variants with myocardial infarction in Japanese individuals with chronic kidney disease. Thromb Haemost 101: 963-968.
115. Kaplan RC, Smith NL, Zucker S, Heckbert SR, Rice K, et al. (2008) Matrix metalloproteinase-3 (MMP3) and MMP9 genes and risk of myocardial infarction, ischemic stroke, and hemorrhagic stroke. Atherosclerosis 201: 130-137.
116. Samnegard A, Silveira A, Tornvall P, Hamsten A, Ericsson CG, et al. (2006) Lower serum concentration of matrix metalloproteinase-3 in the acute stage of myocardial infarction. J Intern Med 259: 530-536.
117. Hlatky MA, Ashley E, Quertermous T, Boothroyd DB, Ridker P, et al. (2007) Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease. Am Heart J 154: 1043-1051.
118. Squire IB, Evans J, Ng LL, Loftus IM, Thompson MM, (2004) Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail 10: 328-333.
119. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, et al. (2000) Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 106: 55-62.
120. Mungrue IN, Zhao P, Yao Y, Meng H, Rau C, et al. (2011) Abcc6 deficiency causes increased infarct size and apoptosis in a mouse cardiac ischemia-reperfusion model. Arterioscler Thromb Vasc Biol 31: 2806-2812.
121. Miwa K, Higashikata T, Mabuchi H, (2004) Intravascular ultrasound findings of coronary wall morphology in a patient with pseudoxanthoma elasticum. Heart 90: e61.
122. Shimasaki Y, Yasue H, Yoshimura M, Nakayama M, Kugiyama K, et al. (1998) Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with myocardial infarction. J Am Coll Cardiol 31: 1506-1510.
123. Jones SP, Greer JJ, Kakkar AK, Ware PD, Turnage RH, et al. (2004) Endothelial nitric oxide synthase overexpression attenuates myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 286: H276-282.
124. Coskun S, Atalar E, Ozturk E, Yavuz B, Ozer N, et al. (2006) Plasma osteopontin levels are elevated in non-ST-segment elevation acute coronary syndromes. J Natl Med Assoc 98: 1746-1750.
125. Okyay K, Tavil Y, Sahinarslan A, Tacoy G, Turfan M, et al. (2011) Plasma osteopontin levels in prediction of prognosis in acute myocardial infarction. Acta Cardiol 66: 197-202.
126. Murry CE, Giachelli CM, Schwartz SM, Vracko R, (1994) Macrophages express osteopontin during repair of myocardial necrosis. Am J Pathol 145: 1450-1462.
127. Panahloo A, Mohamed-Ali V, Gray RP, Humphries SE, Yudkin JS, (2003) Plasminogen activator inhibitor-1 (PAI-1) activity post myocardial infarction: the role of acute phase reactants, insulin-like molecules and promoter (4G/5G) polymorphism in the PAI-1 gene. Atherosclerosis 168: 297-304.
128. Hindorff LA, Schwartz SM, Siscovick DS, Psaty BM, Longstreth WT Jr, et al. (2002) The association of PAI-1 promoter 4G/5G insertion/deletion polymorphism with myocardial infarction and stroke in young women. J Cardiovasc Risk 9: 131-137.
129. Chong NW, Codd V, Chan D, Samani NJ, (2006) Circadian clock genes cause activation of the human PAI-1 gene promoter with 4G/5G allelic preference. FEBS Lett 580: 4469-4472.
130. Shiffman D, Ellis SG, Rowland CM, Malloy MJ, Luke MM, et al. (2005) Identification of four gene variants associated with myocardial infarction. Am J Hum Genet 77: 596-605.
131. Volpi S, Heaton C, Mack K, Hamilton JB, Lannan R, et al. (2009) Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol Psychiatry 14: 1024-1031.
132. Lund J, Qin QP, Ilva T, Nikus K, Eskola M, et al. (2006) Pregnancy-associated plasma protein A: a biomarker in acute ST-elevation myocardial infarction (STEMI). Ann Med 38: 221-228.
133. Qin QP, Kokkala S, Lund J, Tamm N, Voipio-Pulkki LM, et al. (2005) Molecular distinction of circulating pregnancy-associated plasma protein A in myocardial infarction and pregnancy. Clin Chem 51: 75-83.
134. Iversen KK, Teisner B, Winkel P, Gluud C, Kjoller E, et al. (2011) Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial. Atherosclerosis 214: 203-208.
135. Huang C, Gu H, Zhang W, Manukyan MC, Shou W, et al. (2011) SDF-1/CXCR4 mediates acute protection of cardiac function through myocardial STAT3 signaling following global ischemia/reperfusion injury. Am J Physiol Heart Circ Physiol 301: H1496-1505.
136. Wang Y, Johnsen HE, Mortensen S, Bindslev L, Ripa RS, et al. (2006) Changes in circulating mesenchymal stem cells, stem cell homing factor, and vascular growth factors in patients with acute ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Heart 92: 768-774.
137. Ma J, Ge J, Zhang S, Sun A, Shen J, et al. (2005) Time course of myocardial stromal cell-derived factor 1 expression and beneficial effects of intravenously administered bone marrow stem cells in rats with experimental myocardial infarction. Basic Res Cardiol 100: 217-223.
138. He W, Zhang L, Ni A, Zhang Z, Mirotsou M, et al. (2010) Exogenously administered secreted frizzled related protein 2 (Sfrp2) reduces fibrosis and improves cardiac function in a rat model of myocardial infarction. Proc Natl Acad Sci U S A 107: 21110-21115.
139. Kobayashi K, Luo M, Zhang Y, Wilkes DC, Ge G, et al. (2009) Secreted Frizzled-related protein 2 is a procollagen C proteinase enhancer with a role in fibrosis associated with myocardial infarction. Nat Cell Biol 11: 46-55.
140. Jugdutt BI, (2009) Limiting Fibrosis after Myocardial Infarction. New England Journal of Medicine 360: 1567-1569.
141. Shiffman D, O'Meara ES, Bare LA, Rowland CM, Louie JZ, et al. (2008) Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 28: 173-179.
142. Leblond J, Laprise MH, Gaudreau S, Grondin F, Kisiel W, et al. (2006) The serpin proteinase inhibitor 8: an endogenous furin inhibitor released from human platelets. Thromb Haemost 95: 243-252.
143. Ikeuchi M, Tsutsui H, Shiomi T, Matsusaka H, Matsushima S, et al. (2004) Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res 64: 526-535.
144. Frantz S, Hu K, Adamek A, Wolf J, Sallam A, et al. (2008) Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction. Basic Res Cardiol 103: 485-492.
145. Feng YJ, Draghi A, Linfert DR, Wu AH, Tsongalis GJ, (1999) Polymorphisms in the genes for coagulation factors II, V, and VII in patients with ischemic heart disease. Arch Pathol Lab Med 123: 1230-1235.
146. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, et al. (1997) A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 90: 1747-1750.
147. Doggen CJ, Cats VM, Bertina RM, Rosendaal FR, (1998) Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 97: 1037-1041.
148. Halapas A, Zacharoulis A, Theocharis S, Karavidas A, Korres D, et al. (2008) Serum levels of the osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, metalloproteinase-1 (MMP-1) and tissue inhibitors of MMP-1 levels are increased in men 6 months after acute myocardial infarction. Clin Chem Lab Med 46: 510-516.
149. Webb CS, Bonnema DD, Ahmed SH, Leonardi AH, McClure CD, et al. (2006) Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation 114: 1020-1027.
150. Tian H, Cimini M, Fedak PW, Altamentova S, Fazel S, et al. (2007) TIMP-3 deficiency accelerates cardiac remodeling after myocardial infarction. J Mol Cell Cardiol 43: 733-743.
151. Kandalam V, Basu R, Abraham T, Wang X, Awad A, et al. (2010) Early activation of matrix metalloproteinases underlies the exacerbated systolic and diastolic dysfunction in mice lacking TIMP3 following myocardial infarction. Am J Physiol Heart Circ Physiol 299: H1012-1023.
152. Hammoud L, Lu X, Lei M, Feng Q, (2011) Deficiency in TIMP-3 increases cardiac rupture and mortality post-myocardial infarction via EGFR signaling: beneficial effects of cetuximab. Basic Res Cardiol 106: 459-471.
153. Shishido T, Nozaki N, Yamaguchi S, Shibata Y, Nitobe J, et al. (2003) Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation 108: 2905-2910.
154. Mersmann J, Berkels R, Zacharowski P, Tran N, Koch A, et al. (2010) Preconditioning by toll-like receptor 2 agonist Pam3CSK4 reduces CXCL1-dependent leukocyte recruitment in murine myocardial ischemia/reperfusion injury. Crit Care Med 38: 903-909.
155. Arslan F, Keogh B, McGuirk P, Parker AE, (2010) TLR2 and TLR4 in ischemia reperfusion injury. Mediators Inflamm 2010: 704202.
156. Oyama J, Blais C Jr, Liu X, Pu M, Kobzik L, et al. (2004) Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 109: 784-789.
157. Wang E, Feng Y, Zhang M, Zou L, Li Y, et al. (2011) Toll-like receptor 4 signaling confers cardiac protection against ischemic injury via inducible nitric oxide synthase- and soluble guanylate cyclase-dependent mechanisms. Anesthesiology 114: 603-613.
158. Fahim MR, Halim SM, Kamel I, (2004) Tumor necrosis factor alpha in patients with acute myocardial infarction. Egypt J Immunol 11: 31-37.
159. Drimal J, Knezl V, Paulovicova E, Drimal D, (2008) Enhanced early after-myocardial infarction concentration of TNF-alpha subsequently increased circulating and myocardial adrenomedullin in spontaneously hypertensive rats. Gen Physiol Biophys 27: 12-18.
160. Ozaki K, Ohnishi Y, Iida A, Sekine A, Yamada R, et al. (2002) Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 32: 650-654.
161. Ozaki K, Tanaka T, (2005) Genome-wide association study to identify SNPs conferring risk of myocardial infarction and their functional analyses. Cell Mol Life Sci 62: 1804-1813.
162. Panoulas VF, Nikas SN, Smith JP, Douglas KM, Nightingale P, et al. (2008) Lymphotoxin 252A>G polymorphism is common and associates with myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis 67: 1550-1556.
163. Hojo Y, Ikeda U, Zhu Y, Okada M, Ueno S, et al. (2000) Expression of vascular endothelial growth factor in patients with acute myocardial infarction. J Am Coll Cardiol 35: 968-973.
164. Matsudaira K, Maeda K, Okumura N, Yoshikawa D, Morita Y, et al. (2012) Impact of low levels of vascular endothelial growth factor after myocardial infarction on 6-month clinical outcome. Results from the Nagoya Acute Myocardial Infarction Study. Circ J 76: 1509-1516.